Exploratory IND studies: A review of Food and Drug Administration Guidance and similar provision in Europe

被引:3
作者
Attarchi, Faraneh [1 ]
机构
[1] Quintiles Inc, Global Regulatory Affairs, Regulatory Affairs Amer, Overland Pk, KS 66211 USA
来源
DRUG INFORMATION JOURNAL | 2007年 / 41卷 / 03期
关键词
exploratory IND; screening IND; microdose; critical path initiative; supporting toxicology; behavior;
D O I
10.1177/009286150704100303
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In contrast to a traditional Investigational New Drug Application (IND), under which typically only one molecule can be investigated, an Exploratory IND provides a sponsor the opportunity to conduct early-stage clinical studies on a series of closely related molecules under the some IND. This provision, therefore, enables sponsors to select the most promising molecule, from a series of closely related molecules, for further development using human subjects. This article provides an overview of the advantages and limitations of this approach to drug development.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 8 条
[1]  
[Anonymous], 2001, GUID IND ICH S7A SAF
[2]  
*EUR MED AG COMM M, 2004, POS PAP NONCL SAF ST
[3]  
*FDA, 1997, GUID IND ICH S2B GEN
[4]  
FDA, 2004, INN STAGN CHALL OPP
[5]  
*FDA, 1996, GUID IND ICH S2A GUI
[6]  
*US DEP HHS, 2006, GUID IND INDS APPR C
[7]  
*US DEP HHS, 1997, GUID IND ICH M3 NONC
[8]  
US Department of Health and Human Services, 2006, GUID IND INV REV EXP